MASSACHUSETTS GENERAL HOSPITAL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Effects of Parathyroid Hormone in Men With Osteoporosis
Phase 3
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00000427
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Alendronate and/or Parathyroid Hormone for Osteoporosis
Phase 2
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: Human parathyroid hormone [hPTH-(1-34)]Drug: alendronate
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT00000400
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Trial of D-Cycloserine in Schizophrenia
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00000371
Glycine and D-Cycloserine in Schizophrenia
Phase 3
Withdrawn
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT00000372
- Locations
- 🇺🇸
Freedom Trail Clinic, Boston, Massachusetts, United States
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
Phase 3
Completed
- Conditions
- ArrhythmiaCardiovascular DiseasesAtrial FibrillationHeart DiseasesThrombophlebitisCerebrovascular AccidentCerebral Embolism and ThrombosisCerebrovascular Disorders
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT00000517
© Copyright 2025. All Rights Reserved by MedPath